BIONIK Laboratories Report 72% Increase in Patient Sessions on Their InMotion® Robotic Devices Since Launch of InMotion Connect ™ Platform
TORONTO & BOSTON – (COMMERCIAL THREAD) – BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation solutions and assistive technology to people with neurological and mobility problems from hospital to home, today announced hospitals and other healthcare facilities using InMotion Connect ™ have seen a 72% increase in patient sessions on InMotion® robotic devices nationwide since the launch of the proprietary data platform last year. During the same period, hospitals also experienced:
58% increase in total session hours (time spent by patients using InMotion® robots)
47% increase in total number of patients using InMotion® robots
65% increase in individual patient treatment time
47% increase in the number of patient repetitions (movements)
Three consecutive quarters of growth in patient sessions from Q4 2020 to Q2 2021.
“We are delighted to report significant growth in key performance metrics such as patient sessions, session length, patient treatment time and repeats with respect to the use of our InMotion.® technologies following the launch and integration of InMotion Connect ™. The InMotion Connect ™ platform improves technology adoption and clinician engagement at every facility, which we have seen firsthand over the past year, ”said Richard Russo, Jr., CEO of interim and financial director of BIONIK. “We believe this positive growth trend will continue as healthcare facilities continue to seek innovative technologies that can further improve the efficiency and quality of patient care. Our cutting-edge robotic solutions, powered by AI and InMotion Connect ™, position BIONIK well as we seek to further penetrate the market. ”
InMotion Connect ™ is a cloud-based data analysis solution that securely streams and stores anonymized data from all connected InMotion® robotic devices to BIONIK’s cloud server hosted by Amazon AWS, providing contextual and relevant data to reach clinicians and hospital management teams when it matters. more. It combines real-time data from each InMotion® robotic device with the knowledge and expertise of BIONIK clinical specialists to collaborate with each clinic to promote the use of robotic devices and support clinician engagement, in the aim to improve patient care. The platform’s reporting capabilities focus on in-depth data analysis with customizable and adaptive dashboards to support effective decision-making for clinicians and for hospital management. BIONIK continues to develop its proprietary data platform, with future iterations potentially providing clinicians with information to predict patient outcomes.
“With any large capital investment, it’s important for directors to understand how assets are being used to ensure both optimal patient care and a return on investment on the purchase,” said Russo. “The adoption of technology is often one of the biggest barriers to success within clinics, so we are proud to offer a solution that can engage clinicians and management in increasing adoption and use of investment and ultimately leading to better patient outcomes. ”
BIONIK currently uses approximately 280 InMotion® robotic systems to help stroke patients and those with other neurological disorders regain arm and hand movement through a combination of sensory-motor and visual cues, as well as ” providing motor learning rehabilitation techniques as needed. the shape of a neurotherapeutic robot. InMotion® robotic therapy guides the patient through specific tasks, aimed at improving motor control of the arm and hand by increasing strength, range of motion and coordination, and helping to provide effective sensorimotor therapy, efficient and intensive.
To learn more, visit our website: https://connect.bioniklabs.com/
About Laboratoires BIONIK Corp.
BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to people with neurological and mobility problems, from hospital to home. The Company has a portfolio of products focused on upper and lower limb rehabilitation for stroke patients and others with reduced mobility, including three products on the market and two products in various stages of development.
For more information, please visit www.BIONIKlabs.com and contact us on Twitter, LinkedIn and Facebook.
All statements in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by the use of the words “may”, “should”, “would”, “will”, “could”, “” s ‘expect’, ‘anticipate’, ‘estimate’, ‘possible’, ‘believe’, ‘intend’, ‘seek’ or ‘project’ or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements may include, without limitation, statements regarding (i) management’s plans and objectives for future operations, including plans or objectives relating to the design, development and marketing of products of robotic rehabilitation and other Company products, (ii) a projection of income (including income / loss), earnings (including profit / loss) per share, capital expenditure, dividends, pipeline potential sales, the capital structure or other financial elements, (iii) the future financial performance of the Company, (iv) the market and projected market for our existing and planned products and (v) the underlying assumptions or relating to any declaration described in points (i), (ii), (iii) or (iv) above.
These forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances, and may not be made because they are based on projections, plans, objectives, beliefs, expectations, estimates and assumptions. of the Company, and are subject to a number of risks and uncertainties and other influences, over which the Company has no control. The actual results and timing of certain events and circumstances may differ materially from those described in forward-looking statements due to these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the inability of the Company to obtain additional funding, the inability to meet national stock exchange listing standards, the significant time and resources associated with the development of our products and the resulting insufficient cash flow and resulting illiquidity, the impact on the business of the Company due to the Covid-19 pandemic, the Company’s going concern qualification, the Company’s inability to develop the Company’s activities, significant government regulation of medical devices and the health sector , the lack of product diversification, the volatility of the Company’s raw material prices and the Company’s failure to implement the the business plans or strategies of the Company. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.